Aherne, Sinéad T. Madden, Stephen F. Hughes, David J. Pardini, Barbara Naccarati, Alessio Levy, Miroslav Vodicka, Pavel Neary, Paul Dowling, Paul Clynes, Martin Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression. <p><strong>BACKGROUND:</strong> Screening for the early detection of colorectal cancer is important to improve patient survival. The aim of this study was to investigate the potential of circulating cell-free miRNAs as biomarkers of CRC, and their efficiency at delineating patients with polyps and benign adenomas from normal and cancer patient groups.</p> <p><strong>METHODS:</strong> The expression of 667 miRNAs was assessed in a discovery set of 48 plasma samples comprising normal, polyp, adenoma, and early and advanced cancer samples. Three miRNAs (miR-34a, miR-150, and miR-923) were further examined in a validation cohort of 97 subjects divided into the same five groups, and in an independent public dataset of 40 CRC samples and paired normal tissues.</p> <p><strong>RESULTS:</strong> High levels of circulating miR-34a and low miR-150 levels distinguished groups of patients with polyps from those with advanced cancer (AUC = 0.904), and low circulating miR-150 levels separated patients with adenomas from those with advanced cancer (AUC = 0.875). In addition, the altered expression of miR-34a and miR-150 in an independent public dataset of forty CRC samples and paired normal tissues was confirmed.</p> <p><strong>CONCLUSION:</strong> We identified two circulating miRNAs capable of distinguishing patient groups with different diseases of the colon from each other, and patients with advanced cancer from benign disease groups.</p> Colorectal cancer;Circulating miRNAs;miR-34a;miR-150;miR-923;Physiology;Medical Physics 2019-11-23
    https://repository.rcsi.com/articles/journal_contribution/Circulating_miRNAs_miR-34a_and_miR-150_associated_with_colorectal_cancer_progression_/10792283